Graf Akcie BIIB (Biogen Inc). Diskuze k akciím BIIB. Aktuální informace BIIB.

Základní informace o společnosti Biogen Inc (Akcie BIIB)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 43B
Hodnota podniku (EV) 48.26B
Tržby 11.698B
EBITDA 3.071B
Zisk 1.918B
Růst v tržbách Q/Q -24.63 %
Růst v tržbách Y/Y -19.26 %
P/E (Cena vůči ziskům) 22.07
Forward P/E 0.08
EV/Sales 4.13
EV/EBITDA 15.72
EV/EBIT 26.70
PEG 6.24
Price/Sales 3.68
P/FCF 17.47
Price/Book 4.02
Účetní hodnota na akcii 69.98
Hotovost na akcii 17.07
FCF vůči ceně 5.72 %
Počet zaměstnanců 9,100
Tržba na zaměstnance 1285000
Profit margin 29.76 %
Operating margin 18.94 %
Gross margin 86.57 %
EBIT margin 15.45 %
EBITDA margin 26.25 %
EPS - Zisk na akcii 12.74
EPS - Kvartální růst -44.64 %
EPS - Očekávaný růst příští rok -53.28 %
Return on assets 7.84 %
Return on equity 17.89 %
ROIC 19.25 %
ROCE 8.56 %
Dluhy/Equity 1.30
Čistý dluh/EBITDA 6.24
Current ratio 2.15
Quick Ratio 1.77
Volatilita 2.35
Beta 0.00
RSI 32.67
Cílová cena analytiků 290
Známka akcie (dle analytiků) 2.53
Insider ownership 0.68 %
Institutional ownership 86.31 %
Počet akcií 149.033M
Procento shortovaných akcií 1.35 %
Short ratio 1.36 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 1991
Země United States

Finanční výsledky akcie BIIB

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$13,444.6$14,377.9$13,452.9$12,273.9$11,448.8$10,763.8
Cost Of Goods Sold$1,805.2$1,955.4$1,816.3$1,630$1,478.7$1,240.4
Gross Profit$11,639.4$12,422.5$11,636.6$10,643.9$9,970.1$9,523.399
Research And Development Expenses$3,990.9$2,280.6$2,597.2$2,253.6$1,973.3$2,012.8
SG&A Expenses$2,504.5$2,374.7$2,106.3$1,933.9$1,946.6$2,113.1
Other Operating Income Or Expenses$-54.1$-233.2$-172.7$-175$-479.8$-30.5
Operating Expenses$8,894.5$7,335.301$7,564.3$6,928.1$6,297.1$5,872.8
Operating Income$4,550.1$7,042.6$5,888.601$5,345.801$5,151.7$4,891
Total Non-Operating Income/Expense$497.4$83.3$11$-217$-218.7$-123.7
Pre-Tax Income$5,047.5$7,125.9$5,899.6$5,128.8$4,933$4,767.3
Income Taxes$992.3$1,158$1,425.6$2,458.7$1,237.3$1,161.6
Income After Taxes$4,055.2$5,967.9$4,474$2,670.1$3,695.7$3,605.7
Other Income------
Income From Continuous Operations$4,060.5$5,888.5$4,474$2,670.1$3,695.7$3,593.2
Income From Discontinued Operations------
Net Income$4,000.6$5,888.5$4,430.7$2,539.1$3,702.8$3,547
EBITDA$5,007.3$7,507.3$6,539.101$6,426.801$5,834.4$5,491.399
EBIT$4,550.1$7,042.6$5,888.601$5,345.801$5,151.7$4,891
Basic Shares Outstanding161187205213218231
Shares Outstanding161187205213219231
Basic EPS$24.86$31.47$21.63$11.94$16.96$15.38
EPS - Earnings Per Share$24.80$31.42$21.58$11.92$16.93$15.34
# 2020 2019 2018 2017 2016 2015
Current Ratio1.84041.72332.31882.33752.55342.5993
Long-term Debt / Capital0.410.25050.3130.32020.34940.4103
Debt/Equity Ratio0.69490.44640.45550.47140.53740.6961
Gross Margin86.57386.486.498886.719887.084288.4762
Operating Margin33.843348.982143.77243.554244.997745.4393
EBIT Margin33.843348.982143.77243.554244.997745.4393
EBITDA Margin37.24452.214248.607452.361550.960851.0173
Pre-Tax Profit Margin37.54349.561543.853741.786243.087544.2901
Net Profit Margin29.756240.955232.934920.68732.342332.9531
Asset Turnover0.54610.52790.5320.51890.50050.5519
Inventory Turnover Ratio1.68932.43151.95321.80571.47631.3884
Receiveable Turnover7.02517.64586.8696.86847.94178.7725
Days Sales In Receivables51.956747.738753.137453.141645.959841.6075
ROE - Return On Equity37.99844.144734.331921.194530.47138.3279
Return On Tangible Equity220.7153145.2551106.392165.347579.4603136.8317
ROA - Return On Assets16.493421.621617.691611.288816.154818.4221
ROI - Return On Investment22.418533.08523.58714.407219.825322.6039
Book Value Per Share61.343987.526966.083259.565556.176942.8861
Operating Cash Flow Per Share-11.54957.63298.77360.40094.01294.5489
Free Cash Flow Per Share-11.43768.64099.0924-0.85563.97822.9812

Porovnání s konkurencí: Akcie BIIB

Společnost P/E PEG Růst v tržbách (roční) Růst v EPS Return on equity P/B Profit margin
BIIB 22.07 6.24 -19.26 % -53.28 % 17.89 % 4.02 29.76 %
Akcie ABBV 29.80 1.28 48.31 % 14.49 % 48.79 % 14.67 10.08 %
Akcie AMGN 20.99 1.66 4.87 % -2.29 % 60.57 % 12.44 28.57 %
Akcie ACOR N/A N/A -5.03 % 13.04 % -55.69 % 0.22 -65.11 %
Akcie BIO 5.31 4.34 25.56 % -18.67 % 39.56 % 2.18 149.52 %
Akcie GILD 16.42 0.56 20.13 % -20.85 % 27.79 % 4.69 0.50 %
Akcie JNJ 23.93 1.67 10.79 % 7.27 % 27.01 % 6.67 17.82 %
Akcie ILMN 77.93 2.12 18.35 % 10.78 % 15.76 % 12.58 20.25 %
Akcie PFE 17.66 1.97 4.96 % 50.00 % 19.81 % 3.72 22.95 %

Nedávné obchody insiderů: Akcie BIIB

Jméno Obchod Cena Objem
Michel Vounatsos
Chief Executive Officer
Nákup
30 Nov 2020
$241.31 $748,061
Chirfi Guindo
EVP Glob. Prod Strat and Comm
Option
1 Dec 2020
$243.16 $116,960
Robin Kramer
Vice President and Chief Accounting Officer
Option
3 Dec 2020
$244.09 $18,063
Jesus B Mantas
Director
Nákup
9 Feb 2021
$267.00 $239,766
Susan H Alexander
EVP Chief Legal Off and Corp Sec
Option
12 Feb 2021
$278.03 $1,210,821
Alphonse Galdes
EVP Pharmaceutical Oper and Tech
Option
12 Feb 2021
$278.03 $437,341
Ginger Gregory
EVP and Human Resources
Option
12 Feb 2021
$278.03 $812,682
Chirfi Guindo
EVP Glob. Prod Strat and Comm
Option
12 Feb 2021
$278.03 $877,463
Robin Kramer
SVP and Chief Accounting Officer
Option
12 Feb 2021
$278.03 $92,584
Alfred Sandrock
EVP, Research, and Development
Option
12 Feb 2021
$278.03 $1,238,346
Michel Vounatsos
Chief Executive Officer
Option
12 Feb 2021
$278.03 $4,528,831

Diskuze k akciím BIIB